Windtree Therapeutics Delays Q2 2025 Report Filing Amid Financial Challenges.

Windtree Therapeutics has delayed the filing of its Q2 2025 report due to the need for additional time to finalize financial statements and related disclosures. The company does not expect significant changes in its financial results compared to the same period last year. Windtree faces significant financial challenges with no revenue and considerable net losses, impacting its financial health and stability.

Windtree Therapeutics, Inc. has announced a delay in the filing of its Q2 2025 report. The company stated that it requires additional time to finalize its financial statements and related disclosures. Despite the delay, Windtree expects no significant changes in its financial results compared to the same period last year.

Windtree has been facing significant financial challenges, with no revenue and considerable net losses impacting its financial health and stability. The company's diversified operations, including a cryptocurrency treasury strategy and two promising therapeutic pipelines, have not yet yielded substantial financial returns. The delay in the Q2 report highlights the company's ongoing efforts to address its financial situation and ensure accurate financial reporting.

Windtree's interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C has been encouraging, with the drug showing potential benefits for patients with low blood pressure due to heart failure. The company believes istaroxime can be an important drug innovation for acute decompensated heart failure and cardiogenic shock patients. However, the success of the SEISMiC C Study and the ability to move istaroxime to a global Phase 3 program remain key risks for the company.

The company's forward-looking statements highlight the potential risks and uncertainties related to its financial performance and operational plans. Investors should carefully consider these risks and uncertainties when evaluating Windtree's financial prospects.

References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130951/0/en/Windtree-Announces-Istaroxime-has-been-Chosen-for-a-Plenary-Session-Presentation-at-the-Heart-Failure-Society-of-America-2025.html